Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
about
The clinical implications of gene mutations in chronic lymphocytic leukaemiaTargeting ATM-deficient CLL through interference with DNA repair pathwaysDeciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolutionClinical implications of the molecular genetics of chronic lymphocytic leukemiaTherapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors.Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without ImmunotherapyGenomic and epigenomic heterogeneity in chronic lymphocytic leukemiaATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroupsATM signalling and cancer.SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage.Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemiaThe p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia.High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcomeAssessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice.Distinctive genotypes in infants with T-cell acute lymphoblastic leukaemia.Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia.Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive diseaseATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomicsATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2).Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis.Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia?53BP1 is limiting for NHEJ repair in ATM-deficient model systems that are subjected to oncogenic stress or radiation.Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.The role of bone marrow biopsy examination at diagnosis of chronic lymphocytic leukemia: a reappraisal.Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia.TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia.Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia.The molecular pathogenesis of chronic lymphocytic leukaemia.Chronic lymphocytic leukaemia genomics and the precision medicine era.Significance of Inactivated Genes in Leukemia: Pathogenesis and PrognosisEGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants.
P2860
Q26749214-AF41DFF8-2986-471D-9677-FACA954AC4D7Q26822592-1E682238-6282-4539-9F3E-56753FD68DD3Q26823586-D4D19A7D-E04E-4D6C-8DF5-CB460501642BQ26830955-E97B2314-8437-455F-AB2C-885872DB3DB5Q27852340-191B898C-5999-4646-88A4-2E7B49513911Q27853333-51C7F172-115E-45F1-9DCE-1F0817DC5F68Q28077136-31B78FA3-C801-4BB5-9DE2-BE5247C73656Q28087672-EB504A53-9FEF-4ED5-9EAA-0C2CCCDB3B32Q30768193-EA575160-FACD-42E4-97AA-CE83A4E52D64Q30986040-9C979DBD-A480-45A9-B935-371E73E148AFQ33409459-BC428B17-AC18-4385-924C-F84CA6EB26C5Q33913537-BD274ED2-1881-41B6-86DF-041C15878DE6Q34357377-B1566AB2-11C4-4E93-BAFE-8F14F550D3B7Q34391609-972DA064-1260-4CDF-AA4E-51EBD8EE2B39Q34453174-36E8E75A-6C1F-493E-8DAA-4006A1047882Q35149661-BA9A6D25-BA7A-4DE3-9944-BC9703AE8156Q35859176-66C7C3BA-93E8-482D-8E00-631C347A6139Q35906329-10BE0A8C-A0AB-4B64-BE8C-AB7C4AFC0EC4Q36022313-6357D26D-57BC-471A-9036-2A2427765AFDQ36245171-39A2887E-06A7-4516-8B78-F8F783134C04Q36532587-784EB61F-DEE0-48DE-AFD1-F945577118F0Q36799831-B35014D9-F0D4-4987-98A8-355BCC1D22E4Q36884141-FBD70A12-1E00-40B3-881E-933F523DC453Q36967158-8E15836B-4221-4E28-AAE1-FEEEA8000C3CQ36998431-144CCBB0-1D8E-4CB2-81A7-5ABA0B59CD2DQ37325003-3A4F26EA-B07A-4351-967C-38CE8431A39CQ37532952-FCEA222D-1A65-4CB0-B742-02492ADE00E3Q37618663-FDAF1048-9086-470C-A1D5-244452906BC3Q37684399-0841764C-39B8-4262-81EA-A0A71556A167Q37744796-FAF54AE7-3F72-4AC7-A0D4-9B91F2452418Q38088852-9579A3E3-FF31-4FB0-9546-1D85A821F06CQ38101382-E89A98CA-5EA8-40DC-842C-ACD990A3D53AQ38177771-657B1031-F180-4BB6-8BFF-A0F241DCE488Q38744632-185F8805-D408-4F3A-835A-AB8A8AFC88BDQ38748645-D74C216F-477A-4607-93A8-7B0A6F4B8756Q39263974-A73C2C1E-8D85-4175-AA6D-74193D98AE8AQ39350173-E74E32FD-AF76-4B0D-9CDD-7EEBCD4CEF75Q40455172-221E9A1A-A777-435A-ABF5-5B83BAB9B19DQ40575812-90C9E36F-47E3-4598-82C9-2C99789BD3C3Q40972934-8EB64169-917B-41D6-9324-7861DF3991CE
P2860
Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Biallelic ATM inactivation sig ...... Lymphocytic Leukemia 4 trial.
@en
Biallelic ATM inactivation sig ...... Lymphocytic Leukemia 4 trial.
@nl
type
label
Biallelic ATM inactivation sig ...... Lymphocytic Leukemia 4 trial.
@en
Biallelic ATM inactivation sig ...... Lymphocytic Leukemia 4 trial.
@nl
prefLabel
Biallelic ATM inactivation sig ...... Lymphocytic Leukemia 4 trial.
@en
Biallelic ATM inactivation sig ...... Lymphocytic Leukemia 4 trial.
@nl
P2093
P50
P921
P356
P1476
Biallelic ATM inactivation sig ...... Lymphocytic Leukemia 4 trial.
@en
P2093
A Malcolm R Taylor
Anna Skowronska
Anton Parker
Ceri Oldreive
David Gonzalez
David Oscier
Gulshanara Ahmed
Sue Richards
Tatjana Stankovic
P304
P356
10.1200/JCO.2011.41.0852
P407
P577
2012-10-22T00:00:00Z